RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Phio Pharmaceuticals - Stock

Phio Pharmaceuticals P/E 2024

Phio Pharmaceuticals P/E

-0.16

Ticker

PHIO

ISIN

US71880W3034

WKN

A2PYB0

As of Jun 12, 2024, Phio Pharmaceuticals's P/E ratio was -0.16, a -75.38% change from the -0.65 P/E ratio recorded in the previous year.

The Phio Pharmaceuticals P/E history

Phio Pharmaceuticals Aktienanalyse

What does Phio Pharmaceuticals do?

Phio Pharmaceuticals Corp is a biopharmaceutical company focused on developing therapeutic products for the treatment of cancer and infectious diseases. The company is headquartered in Marlborough, Massachusetts and was founded in 1995. Phio Pharmaceuticals Corp. (formerly RXi Pharmaceuticals Corporation) originated in Worcester, Massachusetts, when founders Craig Mello and other researchers at the University of Massachusetts Medical School discovered how RNA interference (RNAi) could be used to combat diseases. The RNAi technology aims to manipulate the DNA code in cells to block the production of proteins related to disease. This technology has the potential to revolutionize the therapeutic landscape by enabling faster, more efficient, and more precise treatments than previous approaches. Phio has developed unique technologies to selectively deliver RNAi molecules to cancer tissue. The technology utilizes a family of compounds called "self-delivering RNA" (sd-rxRNA). These molecules are capable of targeting cancer cells and destroying them from within without affecting healthy cells. Phio believes that its technology has the potential for broad applications in cancer therapy and aims to treat a variety of cancer types. Phio has also developed a technology platform called "immunostimulatory RNA" (isRNA) that aims to activate the body's immune system to recognize and attack cancer cells. When injected into cancer cells, isRNA molecules can cause the immune system to recognize and attack the cancer cells as foreign. This technology has the potential to create a new class of immunotherapeutics that combines the benefits of RNAi and immunotherapy. Phio also has products in the development phase for the treatment of infectious diseases. It has developed an siRNA program for the inhibition of hepatitis B and is currently working on the development of therapeutics against dengue fever and the Zika virus. Phio has a partnership with the Karolinska Institutet, a world-leading medical university in Stockholm, Sweden, to further develop its sd-rxRNA technology. The collaboration aims to confirm the efficacy and safety of the technology and explore potential new applications in cancer therapy and other disease areas. Phio considers its sd-rxRNA products as a potentially disruptive technology that can reduce the need for conventional chemotherapy and radiation therapies, which can have high toxicity and severe side effects in many patients. The technology has the potential to create effective therapies with minimal side effects. Overall, Phio is an emerging company with a promising technology platform that has the potential to fundamentally change the therapeutic landscape. The partnership with a leading medical university and the comprehensive development pipeline suggest that the company is on track to conduct clinical trials in the near future and possibly achieve successful market launches. Phio Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Phio Pharmaceuticals's P/E Ratio

The Price to Earnings (P/E) Ratio of Phio Pharmaceuticals is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Phio Pharmaceuticals's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Phio Pharmaceuticals is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Phio Pharmaceuticals’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Phio Pharmaceuticals Stock

What is the price-to-earnings ratio of Phio Pharmaceuticals?

The price-earnings ratio of Phio Pharmaceuticals is currently -0.16.

How has the price-earnings ratio of Phio Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Phio Pharmaceuticals has increased by -75.38% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Phio Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Phio Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Phio Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Phio Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Phio Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Phio Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Phio Pharmaceuticals?

Some factors that influence the price-earnings ratio of Phio Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Phio Pharmaceuticals pay?

Over the past 12 months, Phio Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Phio Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Phio Pharmaceuticals?

The current dividend yield of Phio Pharmaceuticals is .

When does Phio Pharmaceuticals pay dividends?

Phio Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Phio Pharmaceuticals?

Phio Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Phio Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Phio Pharmaceuticals located?

Phio Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Phio Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Phio Pharmaceuticals from 6/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/12/2024.

When did Phio Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/12/2024.

What was the dividend of Phio Pharmaceuticals in the year 2023?

In the year 2023, Phio Pharmaceuticals distributed 0 USD as dividends.

In which currency does Phio Pharmaceuticals pay out the dividend?

The dividends of Phio Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Phio Pharmaceuticals

Our stock analysis for Phio Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Phio Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.